Reduced serum hepcidin levels in patients with chronic hepatitis C

Journal of Hepatology

Volumn 51, Issue 5, 2009, Pages 845-852

  Girelli, Domenico ^a   Pasino, Michela ^a   Goodnough, Julia B ^b   Nemeth, Elizabeta ^b   Guido, Maria ^c   Castagna, Annalisa ^a   Busti, Fabiana ^a   Campostrini, Natascia ^a   Martinelli, Nicola ^a   Vantini, Italo ^a   Corrocher, Roberto ^a   Ganz, Tomas ^b   Fattovich, Giovanna ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chronic hepatitis C; Ferritin; Hemochromatosis; Hepcidin; Iron overload

Indexed keywords

FERRITIN; HEPCIDIN; INTERLEUKIN 6; IRON; VIRUS RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS C; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IRON BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDEROSIS; VIRUS LOAD;

ADULT; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CASE-CONTROL STUDIES; FEMALE; FERRITINS; HEPATITIS C, CHRONIC; HUMANS; IRON; IRON OVERLOAD; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 70349746734     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.06.027     Document Type: Article

References (55)

1. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005) 558-567
2. Bialek S.R., and Terrault N.A. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 10 (2006) 697-715
3. Fattovich G., Stroffolini T., Zagni I., and Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004) S35-S50
4. Bonkovsky H.L., Troy N., McNeal K., Banner B.F., Sharma A., Obando J., et al. Iron and HFE or Tfr1 mutations as comorbid factors and progression of chronic hepatitis C. J Hepatol 37 (2002) 848-858
5. Beinker N.K., Voigt M.D., Arendse M., Smit J., Stander I.A., and Kirsch R.E. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 25 (1996) 633-638
6. Chapoutot C., Esslimani M., Joomaye Z., Ramos J., Perney P., Laurent C., et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 46 (2000) 711-714
7. Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis. Semin Liver Dis 16 (1996) 13-30
8. Angelucci E., Muretto P., Nicolucci A., Baronciani D., Erer B., Gaziev J., et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100 (2002) 17-21
9. Guyader D., Thirouard A.S., Erdtmann L., Rakba N., Jacquelinet S., Danielou H., et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 46 (2007) 587-595
10. Nahon P., Sutton A., Rufat P., Ziol M., Thabut G., Schischmanoff P.O., et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 134 (2008) 102-110
11. Olynyk J.K., Reddy K.R., Di Bisceglie A.M., Jeffers L.J., Parker T.I., Radick J.L., et al. Hepatic iron concentration as a predictor of response to interferon-alfa therapy in chronic hepatitis-C. Gastroenterology 108 (1995) 1104-1109
12. Lebray P., Zylberberg H., Hue S., Poulet B., Carnot F., Martin S., et al. Influence of HFE gene polymorphisms on the progression and treatment of chronic hepatitis C. J Viral Hepat 11 (2004) 175-182
13. Di Bisceglie A.M., Bonkovsky H.L., Chopra S., Flamm S., Reddy R.K., Grace N., et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 32 (2000) 135-138
14. Kawamura Y., Akuta N., Sezaki H., Hosaka T., Someya T., Kobayashi M., et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol 40 (2005) 901-906
15. Kageyama F., Kobayashi Y., Kawasaki T., Toyokuni S., Uchida K., and Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 95 (2000) 1041-1050
16. Fontana R.J., Israel J., LeClair P., Banner B.F., Tortorelli K., Grace N., et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, control trial. Hepatology 31 (2000) 730-736
17. Piperno A., Sampietro M., D'Alba R., Roffi L., Fargion S., Parma S., et al. Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 16 (1996) 248-254
18. Fargion S., Fracanzani A.L., Rossini A., Borzio M., Riggio O., Belloni G., et al. Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 97 (2002) 1204-1210
19. Kato J., Kobune M., Nakamura T., Kuroiwa G., Takada K., Takimoto R., et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine level in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61 (2001) 8697-8702
20. Furutani T., Hino K., Okuda M., Gondo T., Nishina S., Kitase A., et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130 (2006) 2087-2098
21. Bonkovsky H.L., Banner B.F., and Rothman A.L. Iron and chronic viral hepatitis. Hepatology 25 (1997) 759-768
22. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 124 (2003) 1509-1523
23. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276 (2001) 7806-7810
24. Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276 (2001) 7811-7819
25. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 46 (2007) 1291-1301
26. Adrews N.C. Forging a field: the golden age of iron biology. Blood 112 (2008) 219-230
27. DeDomenico I., McVey Ward D., and Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 9 (2008) 72-81
28. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
29. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 (2003) 783-788
30. Hentze M.W., Muckenthaler M.U., and Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 117 (2004) 285-297
31. Pietrangelo A., Dierssen U., Valli L., Garuti C., Rump A., Corradini E., et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132 (2007) 294-300
32. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106 (2005) 3710-3717
33. Harrison-Findik D.D., Schafer D., Klein E., Timchenko N.A., Kulaksiz H., Clemens D., et al. Alcohol metabolism-mediated oxidative stress downregulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 281 (2006) 22974-22982
34. Bridle K., Cheung T.K., Murphy T., Walters M., Anderson G., Crawford D.G., et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 30 (2006) 106-112
35. Nishina S., Hino K., Korenaga M., Vecchi C., Pietrangelo A., Mizukami Y., et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 134 (2008) 226-238
36. Miura K., Taura K., Kodama Y., Schnabl B., and Brenner D.A. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 48 (2008) 1420-1429
37. Fujita N., Sugimoto R., Motonishi S., Tomosugi N., Tanaka H., Takeo M., et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 49 (2008) 702-710
38. Ganz T., Olbina G., Girelli D., Nemeth E., and Westerman M. Immunoassay for human serum hepcidin. Blood 112 (2008) 4292-4297
39. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
40. Deugnier Y.M., Loreal O., Turlin B., Guyader D., Jouanolle H., Moirand R., et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 102 (1992) 2050-2059
41. Ludwig J., Hashimoto E., Porayko M.K., Moyer T.P., and Baldus W.P. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 112 (1997) 882-888
42. Bozzini C., Campostrini N., Trombini P., Nemeth E., Castagna A., Tenuti I., et al. Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-Hemochromatosis. Blood Cell Mol Dis 40 (2008) 347-352
43. Cassanelli S., Pignatti E., Montosi G., Garuti C., Mariano M., Campioli D., et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J Hepatol 34 (2001) 523-528
44. Bozzini C., Girelli D., Olivieri O., Martinelli N., Bassi A., De Matteis G., et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 28 (2005) 2061-2063
45. Piperno A., Mariani R., Trombini P., and Girelli D. Hepcidin modulation in human disease: from research to clinic. World J Gastroenterol 15 (2009) 538-551
46. Nemeth E., Roetto A., Garozzo G., Ganz T., and Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood 105 (2005) 1803-1806
47. Trinder D., Ayonrinde O.T., and Olynyk J.K. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology 134 (2008) 348-351
48. Wrighting D.M., and Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 108 (2006) 3204-3209
49. Verga Falzacappa M.V., Vujic Spasic M., Kessler R., Stolte J., Hentze M.W., and Muckenthaler M.U. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109 (2007) 353-358
50. Aoki C.A., Rossaro L., Ramsamooj R., Brandhagen D., Burritt M.F., and Bowlus C.L. Liver hepcidin mRNA correlates with iron stores but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol 39 (2005) 71-74
51. Ferrara F., Ventura P., Vegetti A., Guido M., Abbati G., Corradini E., et al. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol 104 (2009) 605-616
52. Deugnier Y., Turlin B., le Quilleuc D., Moirand R., Loréal O., Messner M., et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Pathol 21 (1997) 669-675
53. Detivaud L., Nemeth E., Boudjema K., Turlin B., Troadec M.B., Leroyer P., et al. Hepcidin levels in humans are correlated with hepatic iron stores, haemoglobin levels, and hepatic function. Blood 106 (2005) 746-748
54. Fujita N. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 13 (2007) 97-104
55. Crosby J.R., Gaarde W.A., Egerston J., McKay R., Sun Y.Q., Freier S., et al. Targeting hepcidin with antisense oligonucletides improves anemia endpoints in mice. Blood 108 (2006) 83A-84A